Journal articles on the topic 'Appelists'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 23 journal articles for your research on the topic 'Appelists.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Ernst, Wolfgang, and Ghislain Thibault. "Ce que nous appelions « l’histoire des médias » : l’exercice de l’archéologie médiatique." Communiquer. Revue de communication sociale et publique, no. 13 (April 9, 2015): 91–106. http://dx.doi.org/10.4000/communiquer.1550.
Full textSchmidt, Jürgen W. "Stefan Appelius: Die Spionin. Olga Raue. CIA-Agentin im Kalten Krieg." Das Historisch-Politische Buch (HPB): Volume 67, Issue 3 67, no. 3 (September 1, 2019): 368–69. http://dx.doi.org/10.3790/hpb.67.3.368.
Full textSergio, Ivan. "Propaganda fascista en Chile: el caso de Cile e Patagonia (1930), de Mario Appelius." Artcultura 23, no. 43 (December 24, 2021): 192–209. http://dx.doi.org/10.14393/artc-v23-n43-2021-64092.
Full textBasilone, Linetto. "Through East Asia to the sound of ‘Giovinezza’: Italian travel literature on China, Korea and Japan during the Fascist ventennio." Modern Italy 24, no. 4 (September 30, 2019): 457–68. http://dx.doi.org/10.1017/mit.2019.52.
Full textBrunetti, Mauro M., and Ermanno Quagiotto. "On a new finding of Euciroa arenosa (Rayneval in Appelius, 1871) for the Lower Pliocene of the Mediterranean Basin (Mollusca Bivalvia Euciroidae)." Biodiversity Journal 12, no. 4 (December 30, 2021): 993–96. http://dx.doi.org/10.31396/biodiv.jour.2021.12.4.993.996.
Full textZarca, Bernard. "Proximités socioprofessionnelles entre germains et entre alliés : une comparaison dans la moyenne durée." Population Vol. 54, no. 1 (January 1, 1999): 37–71. http://dx.doi.org/10.3917/popu.p1999.54n1.0071.
Full textSingh, Abhay, Sarah Sadek, Mark G. Faber, Jeffrey Baron, James E. Thompson, Amanda Przespolewski, Elizabeth A. Griffiths, Eunice S. Wang, and Swapna Thota. "The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes." Blood 134, Supplement_1 (November 13, 2019): 5095. http://dx.doi.org/10.1182/blood-2019-132040.
Full textVachhani, Pankit, Kyle Wiatrowski, Pragya Srivastava, Lisa King, Jody Manischewitz, Hana Golding, Heather L. Bashaw, et al. "Quantification of Humoral Immune Response to Influenza Vaccination in MDS." Blood 134, Supplement_1 (November 13, 2019): 4756. http://dx.doi.org/10.1182/blood-2019-126176.
Full textSrivastava, Pragya, Stephanie Tzetzo, Eduardo Cortes Gomez, Kevin Eng, Prashant K. Singh, Kitty De Jong, Sheila N. J. Sait, et al. "Inhibition of LSD1 in Myelodysplastic Syndrome Progenitors Restores Differentiation of CD141Hi Conventional Dendritic Cells." Blood 134, Supplement_1 (November 13, 2019): 1695. http://dx.doi.org/10.1182/blood-2019-126220.
Full textBaron, Jeffrey, Christina L. Lombardi, Han Yu, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Swapna Thota, and Eunice S. Wang. "Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study." Blood 134, Supplement_1 (November 13, 2019): 3501. http://dx.doi.org/10.1182/blood-2019-131629.
Full textThota, Swapna, Abhay Singh, Sarah Sadek, Mark G. Faber, Jeffrey Baron, Amro Elshoury, James E. Thompson, Amanda Przespolewski, Elizabeth A. Griffiths, and Eunice S. Wang. "Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone." Blood 134, Supplement_1 (November 13, 2019): 2645. http://dx.doi.org/10.1182/blood-2019-131633.
Full textWang, Youjin, Weiyin Zhou, Lisa J. McReynolds, Elizabeth A. Griffiths, Swapna Thota, Mitchell Machiela, Stephen J. Chanock, et al. "De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples." Blood 134, Supplement_1 (November 13, 2019): 1430. http://dx.doi.org/10.1182/blood-2019-129110.
Full textPandey, Manu, Mahesh Swaminathan, Elizabeth A. Griffiths, James E. Thompson, Amanda Przespolewski, Swapna Thota, Jeffrey Baron, Tara L. Cronin, and Eunice S. Wang. "Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis." Blood 134, Supplement_1 (November 13, 2019): 3866. http://dx.doi.org/10.1182/blood-2019-132123.
Full textPrzespolewski, Amanda, Craig W. Freyer, Wenyan Ji, Tara L. Cronin, Swapna Thota, Elizabeth A. Griffiths, James E. Thompson, et al. "Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia." Blood 134, Supplement_1 (November 13, 2019): 1361. http://dx.doi.org/10.1182/blood-2019-130582.
Full textNavada, Shyamala C., Guillermo Garcia-Manero, Ehab L. Atallah, M. Nabeel Rajeh, Jamile M. Shammo, Elizabeth A. Griffiths, Samer K. Khaled, et al. "Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)." Blood 134, Supplement_1 (November 13, 2019): 566. http://dx.doi.org/10.1182/blood-2019-131676.
Full textWang, Eunice S., Elizabeth A. Griffiths, Roland B. Walter, Martin S. Tallman, Aaron D. Goldberg, Boo Messahel, and Richard M. Stone. "Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)." Blood 134, Supplement_1 (November 13, 2019): 3829. http://dx.doi.org/10.1182/blood-2019-130536.
Full textIssa, Jean-Pierre, Marco Gobbi, Patricia L. Kropf, Pierre Fenaux, Gail J. Roboz, Jiri Mayer, Jürgen Krauter, et al. "Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study." Blood 134, Supplement_1 (November 13, 2019): 4235. http://dx.doi.org/10.1182/blood-2019-129614.
Full textGriffiths, Elizabeth A., Hagop M. Kantarjian, Casey L. O'Connell, Karen W. L. Yee, Wendy Stock, Naval G. Daver, Elias Jabbour, et al. "Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients." Blood 134, Supplement_1 (November 13, 2019): 1319. http://dx.doi.org/10.1182/blood-2019-131394.
Full textRoboz, Gail J., Hartmut Döhner, Marco Gobbi, Patricia L. Kropf, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, et al. "Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles." Blood 134, Supplement_1 (November 13, 2019): 2591. http://dx.doi.org/10.1182/blood-2019-127253.
Full textGarcia-Manero, Guillermo, James McCloskey, Elizabeth A. Griffiths, Karen W. L. Yee, Amer M. Zeidan, Aref Al-Kali, Kim-Hien Dao, et al. "Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine." Blood 134, Supplement_1 (November 13, 2019): 846. http://dx.doi.org/10.1182/blood-2019-122980.
Full textYee, Karen W. L., Gail J. Roboz, Casey L. O'Connell, Elizabeth A. Griffiths, Raoul Tibes, Katherine J. Walsh, Wendy Stock, et al. "Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response." Blood 134, Supplement_1 (November 13, 2019): 3846. http://dx.doi.org/10.1182/blood-2019-129845.
Full textWang, Michael, Jacqueline C. Barrientos, Richard R. Furman, Matthew Mei, Paul M. Barr, Michael Y. Choi, Sven de Vos, et al. "VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 13–14. http://dx.doi.org/10.1182/blood-2020-136373.
Full textSavona, Michael R., Hagop M. Kantarjian, Gail J. Roboz, Casey L. O'Connell, Katherine J. Walsh, Raoul Tibes, Karen W. L. Yee, et al. "Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration." Blood 134, Supplement_1 (November 13, 2019): 2957. http://dx.doi.org/10.1182/blood-2019-129962.
Full text